Summary
Eli Lilly & Company (LLY) filed an 8-K on October 23, 2008, to report its financial results for the quarter ended September 30, 2008, and to announce a new director appointment. The company detailed significant charges impacting its GAAP results for the quarter, primarily related to Zyprexa investigations and settlements, asset impairments from site closures, and acquired in-process research and development from acquisitions. These non-GAAP adjustments, which Lilly believes provide a clearer view of ongoing operations, are substantial and affect year-over-year comparisons. Investors should pay close attention to these adjustments when evaluating the company's underlying performance and future financial expectations. The filing also introduced Douglas R. Oberhelman as a new independent director to the board.
Key Highlights
- 1Eli Lilly reported Q3 2008 results, with significant non-GAAP adjustments impacting net income.
- 2A substantial charge of $1.477 billion (or $1.33 per share) was recorded due to pending Zyprexa investigations and multi-state resolutions.
- 3Asset impairments and restructuring charges of $182.4 million (or $0.11 per share) were incurred, primarily linked to the sale of the Greenfield, Indiana site.
- 4Acquired in-process research and development costs of $28.0 million (or $0.03 per share) related to the SGX acquisition were also noted.
- 5The company provided non-GAAP financial information, excluding these items, to offer a clearer view of ongoing operational performance.
- 6Douglas R. Oberhelman, Group President of Caterpillar, Inc., was elected to the Board of Directors and nominated for shareholder election.
- 7The filing references prior period adjustments and special charges, emphasizing the company's ongoing use of non-GAAP measures for performance evaluation.